Table 3. Essential Characteristics of Anti-SARS-CoV 2 Virus NP and SARS NP Antibodies.
Reactivity in CELIXSYS*
method (%)

Epitope
Group

A
B

C

D

E

F

G

H

I

J

K

BMR
Cat No.

Clone No.

BMRnp101 S2N2-1710
BMRnp103 S2N2-1898
BMRnp109 S2N4-294
BMRnp111 S2N4-434
BMRnp115 S2N4-1121
BMRnp106 S2N3-2009
BMRnp110 S2N4-309
BMRnp112 S2N4-555
BMRnp102 S2N2-1817
BMRnp107 S2N4-264
BMRnp117 S2N4-1262
BMRnp116 S2N4-1186
BMRnp218 S2N4-1324
BMRnp202 S2N2-572
BMRnp210 S2N4-839
BMRnp209 S2N4-495
BMRnp206 S2N3-104
BMRnp214 S2N4-1198
BMRnp207 S2N3-1014
BMRnp212 S2N4-1098
BMRnp215 S2N4-508
BMRnp211 S2N4-927
BMRnp217 S2N4-1237
BMRnp203 S2N2-1565
BMRnp201 S2N1-1886
BMRnp204 S2N2-1882
BMRnp205 S2N2-2149
BMRnp208 S2N3-2158
BMRnp213 S2N3-235
BMRnp3108 S2N4-268
BMRnp3113 S2N4-834
BMRnp3114 S2N4-884
BMRnp307 S2N4-26
BMRnp302 S2N2-598
BMRnp303 S2N2-789
BMRnp305 S2N4-6
BMRnp312 S2N4-522
BMRnp314 S2N4-726
BMRnp310 S2N4-277
BMRnp304 S2N2-1736
BMRnp315 S2N4-1094
BMRnp301 S2N1-1211
BMRnp317 S2N4-1467

Mouse
Ig
Isotype

Recombinant
WT SARSCoV-2 NP(Full length)

Native
SARS
CoV-2
NP

SARSCoV-2
NP
Full length

Ag-ELISA method (A490nm)

Epitope analysis based on antibody inhibition teston Ag-ELISA method

Nucleo proteins (NP) of SARS-CoV-2 variants or related Corona viruses

Inhibitiion ratio
to each biotinylated antibody in %B.1.1.7

B.1.617.2αδ

SARSCoV-2
NP Variant

SARSCoV-2
NP

D3L,
R203K,
G204R,S235F

D63G,
R203M,
D377Y

B.1.1.529
Ο
SARSCoV-2
NP
P13L,
ERS 31-33
deletion,
R203K,D204R

SARS
CoV-2 SARS MERS OC43 HKU1 229E NL63
NP
NP
NP
NP
NP
NP
NP

His- S2N2- S2N4- S2N4- S2N2- S2N3- S2N4tag 1898 884
434
572 1014
6

180418aa

Ab Conc.
10ug/mL

Ab Conc.
1ug/mL

C.sup X1

IgG1

99

98

62

3.337

2.658

3.368

3.382

0.049

0.063

0.048

0.058

0.073

0.090

0.094

0.075

97

85

23

12

1

28

IgG1

99

94

68

3.272

2.859

3.586

3.512

0.075

0.046

0.045

0.055

0.147

0.076

0.080

0.074

96

78

25

15

4

27

IgG1

99

81

68

3.389

2.609

2.915

3.447

0.049

0.136

0.080

0.090

0.180

0.059

0.068

0.085

93

79

18

8

0

7

IgG1

96

86

66

3.242

2.726

3.167

3.433

0.060

0.062

0.050

0.052

0.068

0.071

0.062

0.073

72

35

93

11

2

5

IgG1

97

87

73

3.209

2.781

3.356

3.433

0.052

0.073

0.070

0.055

0.049

0.087

0.052

0.071

76

43

94

23

9

10

IgG1

97

78

74

3.571

2.459

3.431

3.245

0.087

0.071

0.047

0.085

0.118

0.122

0.079

0.093

59

27

29

18

0

93

IgG1

97

96

77

3.534

2.876

3.290

3.487

0.053

0.049

0.049

0.070

0.075

0.067

0.072

0.081

81

33

18

16

0

12

IgG1

97

92

58

3.350

2.080

3.115

2.868

0.060

0.059

0.047

0.054

0.081

0.064

0.059

0.076

66

31

22

6

6

12

IgG1

98

93

64

3.439

2.437

3.406

3.250

0.057

0.220

0.045

0.127

0.119

0.074

0.077

0.080

59

15

20

7

6

18

IgG1

96

90

64

3.439

2.030

3.043

2.903

0.052

0.047

0.046

0.066

0.062

0.052

0.060

0.074

62

38

24

26

2

21

IgG2a

98

95

71

3.927

3.571

3.758

3.718

0.051

0.074

0.059

0.055

0.141

0.086

0.064

0.081

56

32

14

11

1

15

IgG2a

97

73

70

3.916

3.542

3.775

3.724

0.052

0.329

0.069

0.053

0.265

0.068

0.064

0.082

35

22

21

15

3

16

IgG1

98

89

74

3.299

2.399

3.515

3.389

1.361

0.121

0.049

0.064

0.069

0.066

0.057

0.071

77

34

95

20

3

9

IgG1

98

80

66

2.852

1.874

2.926

3.184

3.700

0.048

0.052

0.047

0.079

0.058

0.066

0.070

6

0

7

82

0

5

IgG2b

87

89

77

3.520

3.328

3.560

3.546

3.543

0.086

0.051

0.050

0.095

0.058

0.067

0.072

16

9

22

69

0

3

IgG2b

98

95

77

3.546

3.367

3.515

3.662

3.775

0.072

0.052

0.057

0.166

0.063

0.068

0.083

0

5

2

61

5

2

IgG2a

99

92

75

3.542

3.207

3.543

3.710

3.884

0.065

0.058

0.050

0.070

0.095

0.060

0.075

4

5

7

67

2

4

IgG2a

100

90

77

3.517

2.916

3.743

3.670

4.000

0.073

0.046

0.065

0.077

0.063

0.062

0.073

6

4

4

58

0

3

IgG2a

97

96

76

3.871

3.866

3.706

3.890

3.905

0.097

0.062

0.058

0.088

0.106

0.069

0.075

0

4

14

35

88

10

IgG2a

97

97

73

3.902

3.856

3.894

3.910

3.754

0.111

1.463

0.051

0.225

0.055

0.072

0.074

15

7

16

30

87

11

IgG1

97

96

70

3.778

3.307

3.791

3.772

4.000

0.068

0.326

0.054

0.209

0.101

0.072

0.080

5

0

9

30

86

6

IgG1

97

96

68

3.786

3.648

3.784

3.771

3.647

0.109

0.213

0.051

0.230

0.054

0.060

0.069

7

6

16

25

85

9

IgG1

96

96

67

3.660

3.387

3.707

3.664

3.849

0.170

0.071

0.067

0.175

0.081

0.088

0.093

21

10

12

20

84

6

IgG1

100

99

76

3.375

3.708

3.630

3.799

3.843

0.124

0.067

0.049

0.085

0.048

0.057

0.068

4

3

12

10

4

7

IgG1

98

22

70

0.366

1.284

2.979

2.320

3.491

0.078

0.052

0.049

0.071

0.063

0.067

0.079

0

6

6

14

0

0

IgG2a

100

99

80

3.834

3.882

3.831

3.918

3.925

0.315

0.057

0.051

0.201

0.054

0.067

0.070

7

1

7

10

5

10

IgG1

99

97

75

3.403

3.301

0.066

3.657

3.830

0.116

0.096

0.048

0.135

0.077

0.061

0.080

11

5

14

23

4

7

IgG1

99

95

81

2.305

1.907

2.863

2.854

3.721

0.062

0.058

0.050

0.183

0.078

0.064

0.087

0

4

3

15

0

0

IgG2a

100

98

72

3.179

2.570

3.751

3.508

3.980

0.090

0.056

0.059

0.076

0.083

0.071

0.083

11

2

7

21

0

3

IgG1

100

98

72

3.480

3.177

3.648

3.613

0.051

1.368

0.047

0.065

0.074

0.072

0.067

0.074

97

90

20

22

5

20

IgG1

100

100

75

3.524

3.234

3.667

3.634

0.065

2.052

0.094

0.088

0.173

0.057

0.062

0.082

99

97

23

17

7

25

IgG2a

100

100

79

3.816

3.801

3.837

3.876

0.082

2.399

0.082

0.072

0.212

0.095

0.071

0.074

99

96

21

23

8

29

IgG1

100

100

75

3.481

3.010

3.694

3.644

0.053

3.285

0.068

0.073

0.049

0.092

0.063

0.070

100

98

21

14

5

23

IgG2a

97

89

64

3.820

3.776

3.829

3.848

0.047

4.000

0.074

0.046

0.211

0.147

0.057

0.076

0

11

94

21

4

55

IgG1

98

93

62

3.485

3.258

3.584

3.658

0.054

3.925

0.101

0.050

0.069

0.065

0.057

0.074

0

10

95

15

3

28

IgG2a

96

95

68

3.765

3.734

3.758

3.774

0.063

3.844

0.057

0.057

0.064

0.068

0.076

0.079

42

20

21

9

6

89

IgG2a

98

95

74

3.778

3.674

3.788

3.793

0.086

3.873

0.059

0.082

0.084

0.086

0.066

0.092

32

17

16

11

0

89

IgG1

94

94

71

3.439

2.479

3.492

3.433

0.055

3.474

0.049

0.051

0.056

0.055

0.068

0.070

48

18

22

12

0

88

IgG1

97

95

74

3.417

2.507

3.580

3.469

0.048

3.769

0.092

0.049

0.048

0.076

0.058

0.070

45

14

21

18

2

85

IgG2a

72

20

60

3.834

3.826

3.833

3.833

0.070

4.000

0.059

0.063

0.153

0.078

0.078

0.084

0

4

11

9

1

6

IgG1

98

94

73

3.335

1.824

3.437

3.183

0.064

3.442

0.051

0.077

0.098

0.073

0.063

0.067

75

25

18

14

0

10

IgG1

85

67

62

2.790

2.109

1.764

3.079

0.073

1.965

0.053

0.052

0.236

0.063

0.060

0.072

63

42

42

18

6

9

IgG1

87

70

68

3.102

2.166

3.168

3.013

0.069

3.467

0.066

0.049

0.066

0.122

0.065

0.066

30

12

12

2

1

51

Ab Conc. =1ug/mL

Ab Conc. =1ug/mL* The CELIXSYS method is an immuno-precipitation-equivalent method. The figure represents the strength of reactivity of monoclonal antibodies to each SARS-CoV-2 virus nucleoprotein.
The higher the figure, the stronger the reactivity of the antibody.
Catalog numbers in purple have changed catalog numbers in January 2023.
Catalog numbers in red are clones newly added in January 2023.

Summary of Technical Data Sheet for BMR Anti-Influenza A Monoclonal Antibody＊Contact us for matching pairs

Product Name

Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody

BMR Catalog No.

BMRnp101

BMRnp102

BMRnp103

BMRnp106

BMRnp107

BMRnp109

BMRnp110

BMRnp111

Clone Number

S2N2-1710

S2N2-1817

S2N2-1898

S2N3-2009

S2N4-264

S2N4-294

S2N4-309

S2N4-434

Lot Number

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Isotype

IgG1

IgG1

IgG1

IgG1

IgG1

IgG1

IgG1

IgG1

Concentration

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

Host

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Immunogen

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)Specificity

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

Cross Reactivity

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of MERS-CoV NP, HCoV-OC43
NP, HCoV-HKU1 NP, HCoV-229E NP and
HCoV-NL63 NP. However, slight crossreactivity with SARS-CoV NP recombinant
protein was confirmed.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

Grade & Purity

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

Form & Buffer

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Storage

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Method of Purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Size

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

Contaminants

NA

NA

NA

NA

NA

NA

NA

NA

Preservative

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

Biohazard
Information

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

Bio Matrix Reseach Inc.

Summary of Technical Data Sheet for BMR Anti-Influenza A Monoclonal Antibody＊Contact us for matching pairs

Product Name

Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody

BMR Catalog No.

BMRnp112

BMRnp115

BMRnp116

BMRnp117

BMRnp201

BMRnp202

BMRnp203

BMRnp204

Clone Number

S2N4-555

S2N4-1121

S2N4-1186

S2N4-1262

S2N1-1886

S2N2-572

S2N2-1565

S2N2-1882

Lot Number

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Isotype

IgG1

IgG1

IgG2a

IgG2a

IgG1

IgG1

IgG1

IgG2a

Concentration

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

Host

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Immunogen

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)Specificity

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

Cross Reactivity

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of MERS-CoV NP, HCoV-OC43
NP, HCoV-229E NP and HCoV-NL63 NP.
However, slight cross-reactivity with SARSCoV NP and HCoV-HKU1 NP
recombinant protein was confirmed.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of MERS-CoV NP, HCoV-OC43
NP, HCoV-229E NP and HCoV-NL63 NP.
However, slight cross-reactivity with SARSCoV NP and HCoV-HKU1 NP
recombinant protein was confirmed.

Grade & Purity

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

Form & Buffer

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Storage

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Method of Purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Size

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

Contaminants

NA

NA

NA

NA

NA

NA

NA

NA

Preservative

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

Biohazard
Information

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

Bio Matrix Reseach Inc.

Summary of Technical Data Sheet for BMR Anti-Influenza A Monoclonal Antibody＊Contact us for matching pairs

Product Name

Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody

BMR Catalog No.

BMRnp205

BMRnp206

BMRnp207

BMRnp208

BMRnp209

BMRnp210

BMRnp211

BMRnp212

Clone Number

S2N2-2149

S2N3-104

S2N3-1014

S2N3-2158

S2N4-495

S2N4-839

S2N4-927

S2N4-1098

Lot Number

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Isotype

IgG1

IgG2a

IgG2a

IgG1

IgG2b

IgG2b

IgG1

IgG2a

Concentration

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

Host

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Immunogen

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)Specificity

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

Cross-reactivity with MERS-CoV NP
recombinant protein was confirmed. Slightcross-reactivity with HCoV-HKU1 NP
recombinant protein was confirmed. No
cross-reactivity with recombinant proteins of
SARS-CoV NP, HCoV-OC43 NP, HCoV229E NP and HCoV-NL63 NP.

Cross Reactivity

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, HCoV-OC43
NP, HCoV-229E NP and HCoV-NL63 NP.
However, slight cross-reactivity with
MERS-CoV NP and HCoV-HKU1 NP
recombinant protein was confirmed.

Grade & Purity

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

Form & Buffer

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Storage

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Method of Purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Size

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

Contaminants

NA

NA

NA

NA

NA

NA

NA

NA

Preservative

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

Biohazard
Information

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

Bio Matrix Reseach Inc.

Summary of Technical Data Sheet for BMR Anti-Influenza A Monoclonal Antibody＊Contact us for matching pairs

Product Name

Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody

BMR Catalog No.

BMRnp213

BMRnp214

BMRnp215

BMRnp217

BMRnp218

BMRnp301

BMRnp302

BMRnp303

Clone Number

S2N3-235

S2N4-1198

S2N4-508

S2N4-1237

S2N4-1324

S2N1-1211

S2N2-598

S2N2-789

Lot Number

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Isotype

IgG2a

IgG2a

IgG1

IgG1

IgG1

IgG1

IgG2a

IgG1

Concentration

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

Host

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Immunogen

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)Specificity

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

Cross Reactivity

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, HCoV-OC43
NP, HCoV-229E NP and HCoV-NL63 NP.
However, slight cross-reactivity with
MERS-CoV NP and HCoV-HKU1 NP
recombinant protein was confirmed.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

Cross-reactivity with SARS-CoV NP
recombinant protein was confirmed. Slightcross-reactivity with HCoV-HKU1 NP
recombinant protein was confirmed. No
cross-reactivity with recombinant proteins of
MERS-CoV NP, HCoV-OC43 NP, HCoV229E NP and HCoV-NL63 NP.

Cross-reactivity with SARS-CoV NP
recombinant protein was confirmed. Slightcross-reactivity with HCoV-HKU1 NP
recombinant protein was confirmed. No
cross-reactivity with recombinant proteins of
MERS-CoV NP, HCoV-OC43 NP, HCoV229E NP and HCoV-NL63 NP.

Cross-reactivity with SARS-CoV NP
recombinant protein was confirmed. No
cross-reactivity with recombinant proteins of
MERS-CoV NP, HCoV-OC43 NP, HCoVHKU1 NP, HCoV-229E NP and HCoVNL63 NP.

Grade & Purity

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

Form & Buffer

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Storage

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Method of Purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Size

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

Contaminants

NA

NA

NA

NA

NA

NA

NA

NA

Preservative

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

Biohazard
Information

This product contains 0.13% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.13% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.13% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.13% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.13% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

Bio Matrix Reseach Inc.

Summary of Technical Data Sheet for BMR Anti-Influenza A Monoclonal Antibody＊Contact us for matching pairs

Product Name

Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody Anti-SARS-CoV-2 NP Monoclonal Antibody

BMR Catalog No.

BMRnp304

BMRnp305

BMRnp307

BMRnp310

BMRnp312

BMRnp314

BMRnp315

BMRnp3108

Clone Number

S2N2-1736

S2N4-6

S2N4-26

S2N4-277

S2N4-522

S2N4-726

S2N4-1094

S2N4-268

Lot Number

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Isotype

IgG2a

IgG2a

IgG1

IgG1

IgG2a

IgG1

IgG1

IgG1

Concentration

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

Host

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653 myeloma
cells with spleen cells from BALB/c mice.
Source : Ascites

Immunogen

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)Specificity

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

SARS-CoV-2 NP (full length) recombinant
protein.

Cross Reactivity

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

Cross-reactivity with SARS-CoV NP
recombinant protein was confirmed. No
cross-reactivity with recombinant proteins of
MERS-CoV NP, HCoV-OC43 NP, HCoVHKU1 NP, HCoV-229E NP and HCoVNL63 NP.

Cross-reactivity with SARS-CoV NP
recombinant protein was confirmed. No
cross-reactivity with recombinant proteins of
MERS-CoV NP, HCoV-OC43 NP, HCoVHKU1 NP, HCoV-229E NP and HCoVNL63 NP.

Cross-reactivity with SARS-CoV NP
recombinant protein was confirmed. No
cross-reactivity with recombinant proteins of
MERS-CoV NP, HCoV-OC43 NP, HCoVHKU1 NP, HCoV-229E NP and HCoVNL63 NP.

Cross-reactivity with SARS-CoV NP
recombinant protein was confirmed. No
cross-reactivity with recombinant proteins of
MERS-CoV NP, HCoV-OC43 NP, HCoVHKU1 NP, HCoV-229E NP and HCoVNL63 NP.

Cross-reactivity with SARS-CoV NP
recombinant protein was confirmed. No
cross-reactivity with recombinant proteins of
MERS-CoV NP, HCoV-OC43 NP, HCoVHKU1 NP, HCoV-229E NP and HCoVNL63 NP.

Cross-reactivity with SARS-CoV NP
recombinant protein was confirmed. No
cross-reactivity with recombinant proteins of
MERS-CoV NP, HCoV-OC43 NP, HCoVHKU1 NP, HCoV-229E NP and HCoVNL63 NP.

Cross-reactivity with SARS-CoV NP
recombinant protein was confirmed. No
cross-reactivity with recombinant proteins of
MERS-CoV NP, HCoV-OC43 NP, HCoVHKU1 NP, HCoV-229E NP and HCoVNL63 NP.

Grade & Purity

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).

Form & Buffer

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied as aliquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Storage

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Method of Purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Size

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

1mg ～

Contaminants

NA

NA

NA

NA

NA

NA

NA

NA

Preservative

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

0.05% NaN3

Biohazard
Information

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.07% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.09% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.11% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.12% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

This product contains 0.05% sodium azide
as a preservative. Although the amount of
sodium azide is very small appropriate caremust be taken when handling.

Bio Matrix Reseach Inc.

Summary of Technical Data Sheet for BMR Anti-Influenza A Monoclonal Antibody＊Contact us for matching pairs

Product Name

Anti-SARS-CoV-2 NP Monoclonal
Antibody

Anti-SARS-CoV-2 NP Monoclonal
Antibody

Anti-SARS-CoV-2 NP Monoclonal
Antibody

BMR Catalog No.

BMRnp3113

BMRnp3114

BMRnp317

Clone Number

S2N4-834

S2N4-884

S2N4-1467

Lot Number

Depend on the purification Lot

Depend on the purification Lot

Depend on the purification Lot

Isotype

IgG1

IgG2a

IgG1

Concentration

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

1 ~ 5 mg/mL
Depend on the purification Lot(5mg/mL for most lots)

Host : Mouse.
Hybridization of P3X63.Ag8.653
myeloma cells with spleen cells from
BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653
myeloma cells with spleen cells from
BALB/c mice.
Source : Ascites

Host : Mouse.
Hybridization of P3X63.Ag8.653
myeloma cells with spleen cells from
BALB/c mice.
Source : Ascites

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

SARS-CoV-2 NP (Recombinant)

Host

Immunogen

SARS-CoV-2 NP (full length)
recombinant protein.

SARS-CoV-2 NP (full length)
recombinant protein.

SARS-CoV-2 NP (full length)
recombinant protein.

Cross Reactivity

No cross-reactivity with recombinant
proteins of SARS-CoV NP, MERS-CoVNP, HCoV-OC43 NP, HCoV-HKU1 NP,
HCoV-229E NP and HCoV-NL63 NP.

Cross-reactivity with SARS-CoV NP
recombinant protein was confirmed. No
cross-reactivity with recombinant proteinsof MERS-CoV NP, HCoV-OC43 NP,
HCoV-HKU1 NP, HCoV-229E NP and
HCoV-NL63 NP.

Cross-reactivity with SARS-CoV NP
recombinant protein was confirmed. No
cross-reactivity with recombinant proteinsof MERS-CoV NP, HCoV-OC43 NP,
HCoV-HKU1 NP, HCoV-229E NP and
HCoV-NL63 NP.

Grade & Purity

In vitro use only. Purity is more than 95% In vitro use only. Purity is more than 95% In vitro use only. Purity is more than 95%(SDS-PAGE or HPLC).
(SDS-PAGE or HPLC).
(SDS-PAGE or HPLC).

Form & Buffer

Protein A affinity purified and supplied asa liquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied asa liquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Protein A affinity purified and supplied asa liquid in PBS(-); pH7.4, 3.0mM KCl,
1.5mM KH2PO4, 140mM NaCl, 8.0mM
Na2HPO4

Storage

Store at 2-8℃

Store at 2-8℃

Store at 2-8℃

Method of Purification

Protein A affinity purification

Protein A affinity purification

Protein A affinity purification

Size

1mg ～

1mg ～

1mg ～

Contaminants

NA

NA

NA

Preservative

0.05% NaN3

0.05% NaN3

0.05% NaN3

Specificity

Biohazard
Information

This product contains 0.05% sodium
azide as a preservative. Although theamount of sodium azide is very small
appropriate care must be taken whenhandling.

This product contains 0.05% sodium
azide as a preservative. Although theamount of sodium azide is very small
appropriate care must be taken whenhandling.

This product contains 0.13% sodium
azide as a preservative. Although theamount of sodium azide is very small
appropriate care must be taken whenhandling.

Bio Matrix Reseach Inc.